The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? in a statement. . Tranquis Therapeutics.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

DECEMBER 13, 2020

Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma. Session Date and Time: 1/17/2021, 2:30 PM-3:15 PM (PST).

Small Molecule 40

Small Molecule FDA Clinical Trials DNA 40

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. Key results include: Total revenues increased 5% to $6.5 on a non-GAAP basis.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

JANUARY 19, 2021

19, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. The offering is expected to close on January 22, 2021, subject to customary closing conditions. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

The Pharma Data

JANUARY 31, 2021

1, 2021 12:16 UTC. Patent US10835501B2, which relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. Cannabinoids are a diverse class of small molecules that interact on the g-coupled receptor subtypes CB1 and CB2.

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 25, 2021

26, 2021 13:00 UTC. –( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Cilia, Jackie; Hitchcock, Stephen (12 August 2021). Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 1c00820.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

The Pharma Data

JUNE 22, 2023

As the global leader in cell therapy, we appreciate the opportunity and responsibility of bringing this innovative treatment to as many eligible patients as possible who may benefit,” said Cindy Perettie, Executive Vice President and Global Head of Kite. “We Kite’s manufacturing facility in El Segundo, California, U.S. Source link: [link]

Therapies 40

Therapies Marketing Small Molecule Science 40

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. for the treatment of post-herpetic neuralgia. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

MARCH 25, 2021

The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. The manuscript was published in the March 25, 2021 issue of NEJM. Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. About Abrocitinib.

Small Molecule 52

Small Molecule Therapies Treatment Disease 52

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

JANUARY 13, 2021

14, 2021 11:00 UTC. These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma,” said Michael Bozik, M.D., Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp. “We

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. FDA for the treatment of Cholangiocarcinoma. TAIPEI and SAN DIEGO , Jan. Chris Recknor at the Center for Advanced Research and Education (CARE) in Gainesville, Georgia.

Trials 52

Trials Treatment Small Molecule Hospitals 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — Q Biomed Inc. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. .

FDA 40

FDA Treatment Small Molecule Drugs 40

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. Sumitovant is a global biopharmaceutical company with a pipeline similarly focused on uterine fibroids, advanced prostate cancer and endometriosis. .

Science 52

Science Small Molecule FDA Approval Therapies 52

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

LifeSciVC

AUGUST 5, 2024

But that initial quote isn’t from 2024, it is from an interview in 2021 with Mark Levin, CEO at Millennium (MIT Technology Review). The proteosome inhibitor, approved for treatment of multiple myeloma and mantle cell lymphoma, has been an important medicine for patients but it isn’t a product of the genomics revolution.

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

JANUARY 6, 2021

7, 2021 11:00 UTC. SAN DIEGO–( BUSINESS WIRE )– Endeavor BioMedicines , a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing. Taladegib is a small-molecule inhibitor of the Hedgehog signaling pathway.

Disease 52

Disease Small Molecule Treatment Therapies 52

The Pharma Data

JANUARY 13, 2021

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. 14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. WO 2021/001458 A1. We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. Cantor Fitzgerald & Co.

FDA Approval 52

FDA Approval Therapies Small Molecule FDA 52

The Pharma Data

MARCH 4, 2021

The new agreement is expected to close by end of March 2021, subject to the satisfaction of customary closing conditions, including review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act. “I Advancing New Treatment Options for DS and LGS Patients. About Soticlestat (TAK-935/OV935).

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Pharma Data

JANUARY 18, 2021

Interim Analysis on Part 1 is expected in Q1 2021. The COVA Study assesses Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

Small Molecule 52

Small Molecule Hospitals Treatment Clinical Trials 52

The Pharma Data

JULY 15, 2021

The company’s proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. There will be no change to Lilly’s 2021 non-GAAP earnings per share guidance as a result of this transaction. Aquilo Partners, L.P.

Small Molecule 52

Small Molecule Engineering Therapies Science 52

The Pharma Data

JULY 18, 2021

Pfizer and BioNTech completed the rolling submission of the BLA in May 2021. On May 10, 2021, the FDA expanded the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to include individuals 12 through 15 years of age.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JANUARY 4, 2021

5, 2021 06:30 UTC. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021. Further details on the trial design will be communicated in H2 2021.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Epub 20230720. doi: 10.1128/jcm.01269-22. Clin Infect Dis. Epub 20151217.

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Pharma Data

OCTOBER 1, 2021

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Clinical Trials 52

Clinical Trials Small Molecule Trials Treatment 52

The Pharma Data

MARCH 18, 2022

In addition to its highly diversified customer base of approximately 530 customers, EUROAPI benefits from a strong and long-term customer relationship with Sanofi, which represented nearly half of EUROAPI’s revenues in 2021. Despite volatile market conditions, Sanofi has decided to move forward with the listing process of EUROAPI.

Small Molecule 52

Small Molecule Marketing Pharmaceuticals Regulations 52

The Pharma Data

JANUARY 3, 2021

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population. million, with the majority to be completed by the first quarter of 2021. SOUTH SAN FRANCISCO, Calif., million – $1.5

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Clinical Development Small Molecule Packaging 52

Metabolite Tales Blog

MAY 12, 2023

In 2021, almost one third of FDA approved drugs contained at least one fluorine. Even newer from the pharma benches are 12 small molecule drugs highlighted by Chris de Savi [4], whose structures were first disclosed at the ACS and AACR meetings in Q1 2023. Molecules 2021, 26, 1160. Angew Chem Int Ed Engl.

Drugs 52

Drugs Small Molecule Metabolic Stability FDA Approval 52

The Pharma Data

JANUARY 24, 2021

25, 2021 12:00 UTC. Biomolecular condensate behavior is linked to numerous neurological diseases where there is a high medical need, including ALS, and I look forward to leading and innovating as part of the team at Faze as we work to transform treatment of these and other serious disorders.”. CAMBRIDGE, Mass.–(

Pharma Companies 52

Pharma Companies Small Molecule Science Disease 52